No profile data available.
Northwest Biotherapeutics, Inc. (NWBO) is a healthcare company in the additional cancer treatment drugs industry, based in Bethesda, United States, with about 105 full-time employees.
It reported revenue of $1.38 million for fiscal year 2025, down 0.3% from fiscal year 2024, and net income of -$61.48 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $807,000, up 516.0% from a year before. Its market capitalization was $272.90 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Northwest Biotherapeutics reported $1.38 million in revenue for fiscal year 2025, down 0.3% from $1.38 million in fiscal year 2024. In Q2 2026 revenue was $807,000.
$272.90 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Prelude Therapeutics Incorporated (PRLD), Perspective Therapeutics, Inc. (CATX), CytoDyn Inc. (CYDY), Fate Therapeutics, Inc. (FATE).